Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032

Description

Japan protein therapeutics market size reached US$ 28.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.60% during 2024-2032. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

Monoclonal Antibodies (mAbs)
Human Insulin
Erythropoietin
Clotting Factors
Fusion Protein
Others

Therapy Area Insights:

Metabolic Disorders
Immunological Disorders
Hematological Disorders
Cancer
Hormonal Disorders
Genetic Disorders
Others

Function Insights:

Enzymatic and Regulatory Activity
Special Targeting Activity
Vaccines
Protein Diagnostics

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan protein therapeutics market?
What is the breakup of the Japan protein therapeutics market on the basis of product?
What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
What is the breakup of the Japan protein therapeutics market on the basis of function?
What are the various stages in the value chain of the Japan protein therapeutics market?
What are the key driving factors and challenges in the Japan protein therapeutics?
What is the structure of the Japan protein therapeutics market and who are the key players?
What is the degree of competition in the Japan protein therapeutics market?

Product Code: SR112024A18904

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

5.1 Historical and Current Market Trends (2018-2023)
5.2 Market Forecast (2024-2032)

6 Japan Protein Therapeutics Market - Breakup by Product

6.1 Monoclonal Antibodies (mAbs)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2018-2023)
- 6.1.3 Market Forecast (2024-2032)
6.2 Human Insulin
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2018-2023)
- 6.2.3 Market Forecast (2024-2032)
6.3 Erythropoietin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2018-2023)
- 6.3.3 Market Forecast (2024-2032)
6.4 Clotting Factors
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2018-2023)
- 6.4.3 Market Forecast (2024-2032)
6.5 Fusion Protein
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2018-2023)
- 6.5.3 Market Forecast (2024-2032)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2018-2023)
- 6.6.2 Market Forecast (2024-2032)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

7.1 Metabolic Disorders
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2018-2023)
- 7.1.3 Market Forecast (2024-2032)
7.2 Immunological Disorders
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2018-2023)
- 7.2.3 Market Forecast (2024-2032)
7.3 Hematological Disorders
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2018-2023)
- 7.3.3 Market Forecast (2024-2032)
7.4 Cancer
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2018-2023)
- 7.4.3 Market Forecast (2024-2032)
7.5 Hormonal Disorders
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2018-2023)
- 7.5.3 Market Forecast (2024-2032)
7.6 Genetic Disorders
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2018-2023)
- 7.6.3 Market Forecast (2024-2032)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2018-2023)
- 7.7.2 Market Forecast (2024-2032)

8 Japan Protein Therapeutics Market - Breakup by Function

8.1 Enzymatic and Regulatory Activity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2018-2023)
- 8.1.3 Market Forecast (2024-2032)
8.2 Special Targeting Activity
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2018-2023)
- 8.2.3 Market Forecast (2024-2032)
8.3 Vaccines
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2018-2023)
- 8.3.3 Market Forecast (2024-2032)
8.4 Protein Diagnostics
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2018-2023)
- 8.4.3 Market Forecast (2024-2032)

9 Japan Protein Therapeutics Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Protein Therapeutics Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis